A diversified testing group with pharmaceutical CRO/bioanalysis operations. Total group revenue must not be presented as pharmaceutical outsourcing revenue.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public financial snapshot
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
Period
Currency / basis
Revenue
Net profit
Operating cash flow
Report
FY2025 2025-12-31
CNY PRC Accounting Standards / consolidated
6,620,735,906.71
1,016,418,093.67 Net income attributable to shareholders of the listed company
Financials represent the listed group’s consolidated totals. Diversified group revenue is not CRO/CDMO segment revenue.
2026Q3 (YTD) · Reporting notes
Financials represent the listed group’s consolidated totals. Diversified group revenue is not CRO/CDMO segment revenue.
Unaudited. Hong Kong interim reports and A-share nine-month reports cover different periods.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
A diversified testing group with pharmaceutical CRO/bioanalysis operations. Total group revenue must not be presented as pharmaceutical outsourcing revenue.
The full 2025 annual report and the 2026 first-nine-month report have been obtained.
Program / service
Target / indication
Representative stage
Evidence & scope
Outsourced services/custom R&D (group also sells products)
Services / platform
Evidence of services, not clinical data for a drug candidate
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Bio-S Pharmaceutical reported that its joint platform with XtalPi, Hangzhou Baijingyao Biotechnology, was unveiled in Shanghai on November 5. The partners described plans to combine AI-driven discovery with experimental validation, drug development, and clinical translation. The November 6 announcement presents an operating strategy and platform milestone, rather than a quantified licensing transaction or validated clinical outcome.
Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.
Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.
Complete service-segment revenue, orders, capacity utilization, and project conversion rates have not been separately verified. Group totals are not a substitute for segment figures.
